Source comparison
Best CJC-1295 Dosage for Sleep: Clinical Data vs Anecdotal Protocols
CJC-1295 DAC Dose 30–60mcg/kg body weight, administered once weekly 100–300mcg flat dose, twice weekly Clinical dosing is weight-adjusted and intended for GH deficiency treatment; flat-dose protocols are empirically derived for sleep and recovery optimization
This comparison does not assign a generated winner or score.
- CJC-1295 DAC Dose
- 30–60mcg/kg body weight, administered once weekly
- 100–300mcg flat dose, twice weekly
- Clinical dosing is weight-adjusted and intended for GH deficiency treatment; flat-dose protocols are empirically derived for sleep and recovery optimization in non-deficient populations. Both work, but the mechanisms differ
- Injection Timing
- Morning administration (7–9 AM)
- 2–3 hours before sleep (8–10 PM for 11 PM bedtime)
- Morning dosing avoids nocturnal hypoglycemia but misses the sleep architecture benefit; evening dosing aligns GH pulse with slow-wave sleep but requires fasting for 2+ hours post-injection to prevent blunted GH response
- Frequency
- Once weekly
- Twice weekly (Monday/Thursday or similar)
- Once-weekly maintains baseline GH elevation; twice-weekly produces more consistent slow-wave sleep metrics because the trough between doses is shorter
- Stacking with Ipamorelin
- Not standard in clinical trials
- 100–200mcg Ipamorelin added to each CJC dose
- Synergistic GH amplification allows dose reduction of CJC-1295 by 30–40% while maintaining equivalent sleep benefit. Reduces fasting glucose elevation
- Cycle Duration
- Continuous (GH deficiency treatment)
- 8–12 weeks on, 4 weeks off
- Continuous use risks receptor downregulation; cycling preserves sensitivity and prevents tolerance. Sleep benefit diminishes after 12–16 weeks without a washout
- Bottom Line
- Clinical protocols prioritize GH normalisation in deficient populations; sleep-focused protocols optimise timing and stacking to amplify the nocturnal GH pulse specifically
- Twice-weekly evening-dosed CJC-1295 at 100–200mcg, optionally stacked with Ipamorelin, is the most validated non-clinical protocol for slow-wave sleep enhancement
- Evening dosing is the defining variable. CJC-1295 administered in the morning produces metabolic benefits but does not meaningfully alter sleep architecture